Go to main contentsGo to search barGo to main menu
Saturday, August 23, 2025 at 11:07 AM

L E T T E R TO THE EDITOR

Dear Editor,

Mental Health Awareness Month in Nevada is a time to push forward — not fall behind. Expanding access to care and encouraging open conversation is only part of the picture. The other piece is making sure future mental health treatments actually reach the patients who need them.

With the Trump administration’s recent executive order comes a lot of concern that innovation could be at risk. This order would base our drug prices on countries that use strict pricing models and often limit or delay access to modern therapies. If we copy those systems, it will be harder to bring future mental health treatments to patients in Nevada and across the country, as investments will be severely depleted.

Additionally, the executive order doesn’t listen to the true concerns of patients. The biggest drivers of patient frustration aren’t always visible. PBMs operate in the background, but their decisions shape what gets covered and how much it costs. Until that’s addressed, no pricing reform will deliver the stability patients are looking for.

Nevada should focus on solutions that protect innovation and make care more stable for those who depend on it. That starts by moving past MFN and toward reforms to PBMs.

Sincerely,
Denise Abbey, LCSW, QMHP

May 27, 2025

 

 

 

More about the author/authors:
Share
Rate

Comment

Comments

C
Carl C. Hagen 06/23/2025 07:47 AM
What are MFNs and PBMs ?? ............................ From the editor: This is a very good question and we apologize for not catching that wasn't in there. We reached out to the writer/submitter and got this info back...hope it's helpful. PBM: Pharmacy Benefit Managers are pharmacies that are owned by insurance companies. (CVS is one.) They negotiate with drug makers to get reduced pricing for medications, but they historically have not passed along those savings to patients. https://www.ftc.gov/system/files/ftc_gov/pdf/pharmacy-benefit-managers-staff-report.pdf MFN: Most Favored Nation pricing is a policy that means a country agrees to offer the same trade concessions (like tariffs or price reductions) to all member nations of the World Trade Organization (WTO). When applied to pharmaceuticals, it could disrupt global access, deter innovation, and obscure the deeper systemic issues in American health care. https://petrieflom.law.harvard.edu/2025/05/22/the-global-risks-of-americas-most-favored-nation-drug-pricing-policy/

SUPPORT OUR WORK